The development and SAR of pyrrolidine carboxamide 11beta-HSD1 inhibitors.
Cheng, H., Hoffman, J., Le, P., Nair, S.K., Cripps, S., Matthews, J., Smith, C., Yang, M., Kupchinsky, S., Dress, K., Edwards, M., Cole, B., Walters, E., Loh, C., Ermolieff, J., Fanjul, A., Bhat, G.B., Herrera, J., Pauly, T., Hosea, N., Paderes, G., Rejto, P.(2010) Bioorg Med Chem Lett 20: 2897-2902
- PubMed: 20363126
- DOI: https://doi.org/10.1016/j.bmcl.2010.03.032
- Primary Citation of Related Structures:
3LZ6 - PubMed Abstract:
The design and development of a series of highly selective pyrrolidine carboxamide 11beta-HSD1 inhibitors are described. These compounds including PF-877423 demonstrated potent in vitro activity against both human and mouse 11beta-HSD1 enzymes. In an in vivo assay, PF-877423 inhibited the conversion of cortisone to cortisol. Structure guided optimization effort yielded potent and stable 11beta-HSD1 selective inhibitor 42.
Organizational Affiliation:
Pfizer Global Research & Development, La Jolla Labs, 10770 Science Center Drive, San Diego, CA 92121, United States. henry.cheng@pfizer.com